Xencor (XNCR) Interest & Investment Income (2013 - 2026)
Xencor (XNCR) reported Interest & Investment Income of $5.5 million for Q1 2026, down 27.58% year-over-year from $7.5 million in Q1 2025, and down 11.95% quarter-over-quarter from $6.2 million in Q4 2025.
Xencor (XNCR) Interest & Investment Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 10 years of Interest & Investment Income data on file, last reported at $5.5 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $5.5 million, down 27.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.4 million (down 17.71% YoY), and the FY2025 annual result was $27.5 million, down 13.8% from the prior year.
- Interest & Investment Income declined to $5.5 million in Q1 2026 per XNCR's latest filing, from $6.2 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $8.5 million in Q1 2024 and troughed at $2.9 million in Q1 2023.
- A 4-year average of $6.8 million and a median of $7.4 million in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2026: Interest & Investment Income soared 194.86% in 2024, then retreated 27.58% in 2026.
- A 4-year view of Interest & Investment Income shows it stood at $2.9 million in 2023, then jumped by 181.61% to $8.2 million in 2024, then declined by 24.06% to $6.2 million in 2025, then decreased by 11.95% to $5.5 million in 2026.
- Business Quant data shows XNCR's Interest & Investment Income at $5.5 million in Q1 2026, $6.2 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 5.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.46 Mn |
| Dec 31, 2025 | 6.20 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | 7.25 Mn |
| Mar 31, 2025 | 7.54 Mn |
| Dec 31, 2024 | 8.16 Mn |
| Sep 30, 2024 | 7.54 Mn |
| Jun 30, 2024 | 7.68 Mn |
| Mar 31, 2024 | 8.55 Mn |
| Mar 31, 2023 | 2.90 Mn |
| Jun 30, 2018 | 2.49 Mn |
| Mar 31, 2018 | 1.16 Mn |
| Dec 31, 2017 | 1.05 Mn |
| Sep 30, 2017 | 1.05 Mn |
| Jun 30, 2017 | 1.04 Mn |
| Mar 31, 2017 | 1.06 Mn |
| Dec 31, 2016 | 785,000.00 |
| Sep 30, 2016 | 579,000.00 |
| Jun 30, 2016 | 368,000.00 |
| Mar 31, 2016 | 359,000.00 |